About the Study

Acute Lymphoblastic Leukemia (ALL) in Infants: A study of blinamtumomab in combination with chemotherapy for infants with newly diagnosed ALL, and randomization of KMT2A-rearranged patients to receive the addition of venetoclax

This study is for: -Infants aged 365 days or less -Who have newly diagnosed ALL The purpose of this study is to evaluate the addition of two cycles of blinatumomab, an immunotherapy drug, to standard chemotherapy for all infants with newly diagnosed ALL, and will investigate in a randomized manner the safety, tolerability, and early activity of venetoclax, a chemotherapy drug, for infants with KMT2A-R ALL.

Interested in learning more?

Full Study Name: AALL2321